Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

Blood (2024) 144 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2024-207345

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Somatic and Germline Cohesin Genes Alterations in Pediatric Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2023-189244

Published: 2023

Journal Articles

Crebbp Mutations Are Associated with Slow Minimal Residual Response to Upfront Induction Chemotherapy in Pediatric High-Hyperdiploid B-Cell Precursor Acute Lymphoblastic Leukemia Treated in the AIEOP-BFM ALL 2009 Protocol

Giacomo Gotti, Daniela Silvestri, Grazia Fazio, Chiara Palmi, Valentino Conter, Maria Grazia Valsecchi, Carmelo Rizzari, Barbara Buldini, Franco Locatelli, Andrea Biondi, Giovanni Cazzaniga

Blood (2023) 142 (Supplement 1): 4344.

https://doi.org/10.1182/blood-2023-187833

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 6367–6368.

https://doi.org/10.1182/blood-2022-169131

Published: 2022

Journal Articles

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Laura Rachele Bettini, Claudia Saitta, Barbara Buldini, Geertruij Te Kronnie, Stefano Rebellato, Daniela Silvestri, Elena Barisone, Andrea Pession, Marco Rabusin, Concetta Micalizzi, Franco Locatelli, MD PhD, Carmelo Rizzari, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Grazia Fazio, Giovanni Cazzaniga, PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-142729

Published: 2020

Journal Articles

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Grazia Fazio, Silvia Bresolin, Claudia Saitta, Daniela Silvestri, Elena Vendramini, Chiara Palmi, Silvia Rigamonti, Marta Galbiati, Manuel Quadri, Stefano Mecca, Angela Maria Savino, Michela Bardini, Andrea Grioni, Maria Grazia Valsecchi, PhD, Geertruy te Kronnie, Andrea Biondi, MD, Giovanni Cazzaniga, PhD

Blood (2019) 134 (Supplement_1): 745.

https://doi.org/10.1182/blood-2019-128509

Published: 2019

Journal Articles

Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection

Elena Varotto, MD PhD, Margarita Maurer-Granofszky, PhD, Daniela Silvestri, Pamela Scarparo, PhD, Ester Mejstrikova, MD PhD, Monika Brüggemann, Giovanni Cazzaniga, PhD, Valentino Conter, MD, Ondrej Hrusak, MD PhD, Giuseppe Gaipa, PhD, Angela Schumich, Maria Grazia Valsecchi, PhD, Giuseppe Basso, MD PhD, Michael Dworzak, MD, Barbara Buldini, MD PhD

Blood (2019) 134 (Supplement_1): 377.

https://doi.org/10.1182/blood-2019-127287

Published: 2019

Journal Articles

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Luciana Vinti, MD, Luisa Strocchio, MD, Barbara Buldini, MD PhD, Daniela Silvestri, Valentino Conter, MD, Pietro Merli, MD, Carmelo Rizzari, Rosanna Parasole, MD, Maddalena Paganin, PhD, Giuseppe Basso, MD PhD, Marco Zecca, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 2580.

https://doi.org/10.1182/blood-2019-131292

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)

Giuseppe Gaipa, PhD, Oscar Maglia, Simona Sala, Bsc, Noemi Marino, Daniela Silvestri, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Valentino Conter, MD

Blood (2018) 132 (Supplement 1): 2827.

https://doi.org/10.1182/blood-2018-99-116782

Published: 2018

Journal Articles

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Irene Della Starza, PhD, Vittorio Nunes, Federica Lovisa, Daniela Silvestri, Marzia Cavalli, PhD, Andrea Garofalo, Mimma Campeggio, Lucia Anna De Novi, PhD, Carlotta Oggioni, Andrea Biondi, MD, Anna Guarini, PhD, Maria Grazia Valsecchi, PhD, Valentino Conter, MD, Giuseppe Basso, MD, Robin Foà, MD, Giovanni Cazzaniga, PhD

Blood (2018) 132 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2018-99-117954

Published: 2018

Journal Articles

Osteonecrosis in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL): A Single-Center Cohort Analysis

Erica Brivio, MD, Andrea Davide Cossio, MD, Davide Borra, MD, Antonella Colombini, MD, Giulia Prunotto, MD, Daniela Silvestri, Adriana Balduzzi, MD

Blood (2018) 132 (Supplement 1): 2663.

https://doi.org/10.1182/blood-2018-99-114910

Published: 2018

Journal Articles

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Erica Dander, PhD, Federica Portale, PhD, Daniela Silvestri, Giulia Cricrì, Silvia Bresolin, PhD, Stefania Gaspari, Barbara Russo, Monica Lupi, Paolo Ubezio, Geertruy te Kronnie, Maria Grazia Valsecchi, PhD, Franco Locatelli, Carmelo Rizzari, MD, Andrea Biondi, MD, Giovanna D'Amico, BSc, PhD MSc

Blood (2018) 132 (Supplement 1): 1296.

https://doi.org/10.1182/blood-2018-99-116668

Published: 2018

Journal Articles

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Blood (2017) 130 (19): 2146–2149.

https://doi.org/10.1182/blood-2017-05-782086

Published: 2017

Includes: Supplemental data

Journal Articles

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

Adriana Balduzzi, MD, Lucia Di Maio, MD, Daniela Silvestri, MS, Simona Songia, BS, Giulia Prunotto, MD, Sonia Bonanomi, MD, Attilio Rovelli, MD, Andrea Biondi, MD, Giovanni Cazzaniga, Maria Grazia Valsecchi, PhD

Blood (2016) 128 (22): 3480.

https://doi.org/10.1182/blood.V128.22.3480.3480

Published: 2016

NARROW

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Somatic and Germline Cohesin Genes Alterations in Pediatric Acute Lymphoblastic Leukemia

Crebbp Mutations Are Associated with Slow Minimal Residual Response to Upfront Induction Chemotherapy in Pediatric High-Hyperdiploid B-Cell Precursor Acute Lymphoblastic Leukemia Treated in the AIEOP-BFM ALL 2009 Protocol

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Osteonecrosis in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL): A Single-Center Cohort Analysis

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only